Clinical trial · Observational
Fertility and Ovarian Reserve in Female Childhood Cancer Survivors
PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Alkylating Agents | — | UNRESOLVED | — |
| CED | — | UNRESOLVED | — |
| Childhood Cancer Survivors | — | UNRESOLVED | — |
| Cryopreservation | — | UNRESOLVED | — |
| Female | — | UNRESOLVED | — |
| Fertility | — | UNRESOLVED | — |
| Ovarian Reserve | — | UNRESOLVED | — |
| Ovarian Reserve Markers | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (6)
- measure
- The index of fertility
- timeFrame
- 2027
- description
- having children among survivors in compared with controls
- measure
- The rate of menopause and POI
- timeFrame
- 2027
- description
- Number of participants in POI
- measure
- The rate of premature or delayed puberty
- timeFrame
- 2027
- description
- Number of participants with premature/delayed puberty
- measure
- The rate of negative pregnancy outcome (miscarriage, medical abortion, stillbirth or birth
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: * Child and adolescent female patients included in the Paediatrics Late Effects Project: * diagnosed with cancer1 between 01/01/2004 and 31/12/2018 * \<17 years old at diagnosis * treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF * alive * ≥ 18 years-old at time of recruitment. Exclusion Criteria: * Cancer diagnosis for controls
References
Publications (0)
Data not yet available